Hypokalaemia is the dominant feature and the main target of treatment in Bartter's syndrome. Other abnormalities include an overstimulated renin-aldosterone system, angiotensin resistance, hyperprostaglandinuria, increased plasma bradykinin and urinary kallikrein excretion (but decreased urinary kinin excretion), and a chloridelosing nephropathy. The cause of this condition has proved to be elusive, and the syndrome has therefore been characterised as the biological counterpart of an integrated electronic circuit.' Drugs directed at various elements of this circuit (for example, beta-blockers, aldosterone antagonists, prostaglandin inhibitors, and amiloride) have all been applied with some degree of success, albeit often only temporary and partial. 2 We report on the long-term administration of the converting-enzyme inhibitor captopril in one patient.
Case report
A 35-year-old man with familial Bartter's syndrome had previously been treated with spironolactone (200 mg daily). During this treatment, which had had to be stopped because of headache and nausea, the serum potassium concentration had risen from 2-8 to 3-8 mmol(mEq)/l. He was admitted to hospital. Before captopril was started the serum potassium concentration had returned to 2-5 mmol/l. Plasma renin activity was raised, and the extracellular fluid volume (volume of distribution of bromine-82) lay below the estimated range (figure). Blood pressure, which fell from 120/75 mm Hg Plasma reninactivity (ftol/i.s) 6700 -870 Fatal pulmonary fibrosis occurring during treatment with cyclophosphamide Pulmonary fibrosis is an uncommon complication of drug treatment and has been reported in association with many cytotoxic drugs.' We describe two patients who developed pulmonary fibrosis while receiving cyclophosphamide for glomerulonephritis.
Case reports
Case 1-A 58-year-old man was admitted to hospital with rigors, anorexia, increasing dyspnoea, and a non-productive cough. For seven weeks he had been taking 100 mg cyclophosphamide and 30 mg prednisolone daily for a rapidly progressive glomerulonephritis, and his renal function had been improving (serum creatinine concentration 311 umol/l; 3-5 mg/100 ml).
Examination showed fever, a tachycardia of 100/min, crepitations at both lung bases, and a left-sided pleural rub. Radiography showed left-sided basal shadowing. Intravenous cefuroxime 750 mg twice daily was given after specimens had been taken for culture. One week later he became acutely unwell, with cyanosis, tachypnoea, intercostal indrawing, a tracheal tug, and increase in intensity of the pleural rub. Blood gas analysis yielded Pco2 2 kPa (15 mm Hg) and Po. 4-7 kPa (35 mm Hg) on air. Chest radiography showed mid-zone and basal shadowing. Cyclophosphamide and cefuroxime were stopped and gentamicin, flucloxacillin, and co-trimoxazole introduced after bronchoscopy. There was no evidence of malignancy, and staining for infective organisms, including Pneumocystis carinii, gave negative results. Necropsy in both cases showed diffuse pulmonary consolidation, histologically the same as that obtained at biopsy and considered to be similar to the fibrosis associated with busulphan treatment.2 In the absence of any evidence of infection we believe that the progressive fibrosis was secondary to cyclophosphamide treatment. This reaction has been reported with low total dosage of cyclophosphamide after short courses3 but to our knowledge not in association with the treatment of renal disease. Only three cases of pulmonary fibrosis in association with cyclophosphamide have been reported to the Committee on the Safety of Medicines. World wide, eight cases have been documented. Resolution, however, often followed withdrawal ofthe drug.34 The mechanism of the reaction remains unsolved.
